Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 11, 2015, Pages 2091-2104

  Fu, Y ^a   Shao, Z M ^b   He, Q Z ^a   Jiang, B Q ^a   Wu, Y ^a   Zhuang, Z G ^a  

^a Shanghai First Maternity and Infant Health Hospital   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Cx43; GJIC; Hsa miR 206; Metastasis; Triple negative breast cancer

Indexed keywords

CONNEXIN 43; CONNEXIN 47; GELATINASE A; GELATINASE B; HSA MICRORNA 206; MICRORNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; GJA1 PROTEIN, HUMAN; MIRN206 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BREAST CANCER CELL LINE; CELL ADHESION; CELL COMMUNICATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LYMPH NODE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CONNEXIN 43; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICRORNAS; NEOPLASM METASTASIS; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84942235469     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. DENT R, TRUDEAU M, PRITCHARD KI, HANNA WM, KAHN HK, SAWKA CA, LICKLEY LA, RAWLINSON E, SUN P, NAROD SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
2. BARTEL DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
3. BUDHU A, JI J, WANG XW. The clinical potential of microRNAs. J Hematol Oncol 2010; 3: 37.
4. YANG J, ZENG Y. Identification of miRNA-mRNA crosstalk in pancreatic cancer by integrating transcriptome analysis. Eur Rev Med Pharmacol Sci, 2015; 19: 825-834.
5. NEGRINI M, CALIN GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res BCR 2008; 10: 203.
6. MA L, TERUYA-FELDSTEIN J, WEINBERG RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
7. ZHU S, WU H, WU F, NIE D, SHENG S, MO YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18: 350-359.
8. LOWERY AJ, MILLER N, MCNEILL RE, KERIN MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008; 14: 360-365.
9. HIDAKA H, SEKI N, YOSHINO H, YAMASAKI T, YAMADA Y, NOHATA N, FUSE M, NAKAGAWA M, ENOKIDA H. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3: 44-57.
10. VICKERS MM, BAR J, GORN-HONDERMANN I, YAROM N, DANESHMAND M, HANSON JE, ADDISON CL, ASMIS TR, JONKER DJ, MAROUN J, LORIMER IA, GOSS GD, DIMITROULAKOS J. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 2012; 29: 123-132.
11. ZHANG T, LIU M, WANG C, LIN C, SUN Y, JIN D. Downregulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res 2011; 31: 3859-3863.
12. CHEN X, YAN Q, LI S, ZHOU L, YANG H, YANG Y, LIU X, WAN X. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett 2012; 314: 41-53.
13. ADAMS BD, FURNEAUX H, WHITE BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21: 1132-1147.
14. KONDO N, TOYAMA T, SUGIURA H, FUJII Y, YAMASHITA H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68: 5004-5008.
15. DAI P, NAKAGAMI T, TANAKA H, HITOMI T, TAKAMATSU T. Cx43 mediates TGF-beta signaling through competitive Smads binding to microtubules. Mol Biol Cell 2007, 18: 2264-2273.
16. CHANG XZ, LI DQ, HOU YF, WU J, LU JS, DI GH, JIN W, OU ZL, SHEN ZZ, SHAO ZM. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
17. ZHUANG ZG, DI GH, SHEN ZZ, DING J, SHAO ZM. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 2006; 4: 843-849.
18. EL-FOULY MH, TROSKO JE, CHANG CC. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res 1987; 168: 422-430.
19. YAN LX, WU QN, ZHANG Y, LI YY, LIAO DZ, HOU JH, FU J, ZENG MS, YUN JP, WU QL, ZENG YX, SHAO Y. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011; 13: R2.
20. GOLDHIRSCH A, WOOD WC, COATES AS, GELBER RD, THURLIMANN B, SENN HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
21. YANG L, WU X, WANG Y, ZHANG K, WU J, YUAN YC, DENG X, CHEN L, KIM CC, LAU S, SOMIO G, YEN Y. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011; 30: 4437-4446.
22. STRATFORD AL, REIPAS K, HU K, FOTOVATI A, BROUGH R, FRANKUM J, TAKHAR M, WATSON P, ASHWORTH A, LORD CJ, LASHAM A, PRINT CG, DUNN SE. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 2012; 30:1338-1348.
23. CHEN X, XU Z, WANG Y. Recent advances in breast cancer metastasis suppressor 1. Int J Biol Markers 2011; 26: 1-8.
24. GRECO SJ, RAMESHWAR P. MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proc Natl Acad Sci USA 2007; 104: 15484-15489.
25. LIU X, HE M, HOU Y, LIANG B, ZHAO L, MA S, YU Y. Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncology Rep 2013; 29: 1215-1220.
26. SONG G, ZHANG Y, WANG L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284: 31921-31927.
27. ADAMS BD, COWEE DM, WHITE BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol 2009; 23: 1215-1230.
28. MESE G, RICHARD G, WHITE TW. Gap junctions: basic structure and function. J Invest Dermatol 2007; 127: 2516-2524.
29. LAIRD DW. The gap junction proteome and its relationship to disease. Trends Cell Biol 2010; 20: 92-101.
30. NAUS CC, LAIRD DW. Implications and challenges of connexin connections to cancer. Nat Rev Cancer 2010; 10: 435-441.
31. CZYZ J. The stage-specific function of gap junctions during tumourigenesis. Cell Mol Biol Lett 2008; 13: 92-102.